Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
1997-10-31
2002-07-02
Wang, Andrew (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C424S130100, C435S006120, C514S04400A, C530S387100, C536S023100, C536S024500
Reexamination Certificate
active
06413939
ABSTRACT:
TECHNICAL FIELD OF THE INVENTION
The present invention provides a novel phosphofructokinase (iPFK-2) isozyme that is preferentially transcribed and translated in tumor cells. The discovery of this isozyme, together with its function, led to the discovery of its use as a diagnostic target, as a drug screening target, and antisense compounds that inhibit its translation in cellular cytosol as an anti-tumor treatment.
BACKGROUND OF THE INVENTION
The glycolytic pathway is a fundamental anaerobic pathway for sugar metabolism in eukaryotic cells. Glycolysis has a dual role, to degrade sugars to generate energy (ATP) and to provide building blocks for synthetic reactions. The rate of conversion of glucose into pyruvate is regulated to meet these two major cellular needs. In glycolysis, the enzymes hexokinase, phosphofructokinase and pyruvate kinase catalyze irreversible reactions and are regulated enzymes for control points in glycolysis. The enzymes are regulated by reversible binding of allosteric effectors, by covalent modification and by transcriptional control to meet changing metabolic needs. Of the three control enzymes, phosphofructokinase is the most important control point in mammalian glycolysis.
In 1930, Warburg pointed out that tumors have a high rate of anaerobic glycolysis and that they do not show a decreased glycolytic rate at relatively high O
2
concentrations. This loss of regulatory control (i.e., the Pasteur effect) has come to be called the Warburg effect. Supplying tumor cells with glucose results in an inhibition of oxygen consumption, which magnifies the dependence on glucose for energy. Other cellular types do not normally show this effect since they maintain respiration from other substrates even in the presence of glucose. The question of why rapidly growing tumors have a marked tendency to convert the glycolytically-generated pyruvate to lactic acid in the cytosol instead of transporting into the mitochondria for total oxidation has puzzled biochemists for years. The physiologic consequence of this altered metabolic behavior are clear. Tumor tissue generates a high degree of metabolic inefficiency in the host, through an enhanced operation of energy-wasting processes, such as the Cori cycle between the tumor and the liver. As a result of the high glycolytic rate, a large amount of pyruvate is generated, together with an increase in the cytosolic NADH/NAD+ratio, which favors the reduction of pyruvate to lactate through the action of lactate dehydrogenase. This is also supported by the low mitochondrial content of tumor cells which hampers the possibility of dissipating NADH through the action of the electron transfer chain and the low levels of NADH-shuttle systems found in a great number of tumors. The tumor cell becomes a lactate exporter in a similar way to some muscular fibers in anoxic situations. Although the precise role of the enhanced Cori cycle in tumor-bearing states is not fully determined, it adds inefficiency to the host in a way that, instead of ATP formation of 36-38 molecules during the complete oxidation of glucose to CO
2
, a net loss of 4 ATPs can be expected when two three-carbon molecules are converted to one molecule of glucose.
A distinctive metabolic environment of cancer-bearing individuals has been described (Argilés and Azcón-Bieto,
Mol. Cell. Biochem.
81:3-17, 1988). Tumor invasion upon a host has been metabolically characterized by a reduction of the metabolic efficiency of the host, muscular protein depletion, increased gluconeogenesis, and uncoupling of oxidative phosphorylation. The net result is an energy imbalance leading to cachexia and eventual starvation.
SUMMARY OF THE INVENTION
The present invention provides a cancer malignancy diagnostic assay comprising obtaining a sample of a body fluid or tissue, performing a sequence identity assay to look for the presence of iPFK-2 specific sequences (SEQ ID NO: 11). Preferably, the sequence identity assay is selected from the group consisting of PCR (polymerase chain reaction) assays, ELISA immunologic assays, hybridization assays, and combinations thereof. The present invention further provides an anticancer, anti-inflammatory and cachexia pharmaceutical composition comprising a specific antisense oligonucleotide to the inventive isolated iPFK-2 sequence and a pharmaceutically acceptable oligonucleotide carrier. Preferably, the antisense oligonucleotide is selected from a 15-50 base oligonucleotide incorporating an oligonucleotide sequence selected from the group consisting of): 5′-AGCCGCGAAGATGCCGTTGG-3′[SEQ ID NO: 1], 5′-CCAACGGCATCTTCGCGGCT-3′[SEQ ID NO: 2], 5′-AAGATGCCGTTGGAACTGAC-3′[SEQ ID NO: 3], 5′-GTCAGTTCCAACGGCATCTT-3′[SEQ ID NO: 4], and combinations thereof. The present invention further provides a therapeutic agent screening assay to screen for compounds having anti-tumor activity, comprising: (a) obtaining recombinant iPFK-2 having activity that forms fructose 2,6-diphosphate from fructose 6-phosphate substrate: (b) adding candidate drug at various concentrations or no-drug control vehicle; and (c) assaying for fructose 2,6-diphosphate as a measure of enzymatic activity. Preferably, the product assay is conducted by means of an enzymatic assay.
The present invention further provides a recombinant iPFK-2 polypeptide expressed by the cDNA sequence provided in SEQ ID NO. 11. The use of the iPFK-2 polypeptide, with known antibody techniques, including known monoclonal antibody techniques, further provides an antibody that specifically binds to iPFK-2. Preferably, this antibody is a monoclonal antibody.
REFERENCES:
patent: 6255046 (2001-07-01), Bucala et al.
Rojanasakul, Antisense oligonucleotide therapeutics: drug delivery and targeting, Advanced Drug Delivery Reviews, vol. 18, pp. 115-131, 1996.*
Gewirtz et al., Facilitating oligonucleotide delivery: Helping antisense deliver on its promise, Proc. Natl. Acad. Sci., vol. 93, pp. 3161-3163, Apr. 1996.*
Branch, A good antisense is hard to find, TIBS, vol. 23, pp. 45-50, Feb. 1998.*
Stein, Hybridization prediction gets to first base, Nature Biotechnology, vol. 17, pp. 751-752, Aug. 1999.*
Argilés, J.M. and Azcón-Bieto, J., The metabolic environment of cancer,Molecular and Cellular Biochemistry81:3-17, 1988.
Sakai, A. et al., Cloning of cDNA Encoding for a Novel Isozyme of Fructose 6-Phosphate,2-Kinase/Fructose 2,6-Bisphosphatase from Human Placenta,J. Biochem.119, 506-511, 1996.
Watanabe, F. et al., Novel Isoforms of Rat Brain Fructose 6-Phosphate 2-Kinase/Fructose 2,6-Bisphophatase Are Generated by Tissue-Specific Alternative Splicing,Journal of Neurochemistry69(1), 1997.
Hamilton et al., Identification of PRG1, A Novel Progestin-Responsive Gene with Sequence Homology to 6-Phosphofructo-2-Kinase/Fructose-2,6-Bisphophatase,Mol. Endocrinology11:490-502, 1997.
Textbook Section entitled Phosphofructokinase is the Key Enzyme in the Control of Glycolysis,Metabolic Energy, Part III, Chapter 19, p. 493-494.
Greenberg, et al., “Control of the Decay of Labile Protooncogene and Cytokine mRNAs”, Control of Messenger RNA Stability, Belasco, et al. (eds.), Academic Press, Inc., New York (1993).
Caput, et al., “Identification of a Common Nucleotide Sequence in the 3′-Untranslated Region of mRNA Molecules Specifying Inflammatory Mediators”, Proc. Natl. Acad. Sci. USA, 83, 1670-1674 (1986).
Shaw, et al., “A Conserved AU Sequence from 3′ Untranslated Region of GM-CSF mRNA Mediates Selective mRNA Degradation”, Cell, 46, 659-667 (1986).
Lange, et al., “Sequence of Human Liver 6-Phosphofructo-2-Kinase/Fructose-2,6-Bisphophatase”, Nucleic Acids Research, 18:12, 3652 (1990).
Lee, et al., “Activation of the Transforming Potential of the Human fos Proto-Oncogene Requires Message Stabilization and Results in Increased Amounts of Partially Modified fos Protein”, Molecular and Cellular Biology, 8:12, 5521-5527 (1988).
Rabbitts, et al., “Truncation of Exon 1 from the c-myc Gene Results in Prolonged c-myc mRNA Stability”, EMBO J., 4, 3727-
Bucala Richard J.
Chesney Jason
Mitchell Robert A.
Kelber Steven B.
Piper Rudnick LLP
The Picower Institute for Medical Research
Wang Andrew
LandOfFree
Inducible phosphofructokinase and the Warburg effect does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inducible phosphofructokinase and the Warburg effect, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inducible phosphofructokinase and the Warburg effect will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2846372